Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Statement re. Press Comment

15 Apr 2005 11:59

Marchpole Holdings PLC15 April 2005 For Immediate Release 15 April 2005 Marchpole Holdings plc Marchpole Holdings plc, which designs, produces and sells high quality clothingand accessories for six world class brands (Yves Saint Laurent, Boateng,Jean-Charles de Castelbajac ('JCC'), Rossignol, Emanuel Ungaro and Ungaro) makesthe following comment in relation to recent press speculation. "The directors note the press comment published this morning. The businessstrategy that has successfully been in place for the past three years has seenMarchpole create a portfolio of high quality brands and licensing arrangements,including, Yves Saint Laurent, Boateng, Jean-Charles de Castelbajac ('JCC'),Rossignol, Emanuel Ungaro and Ungaro." The new business streams have alreadycontributed significantly to the growth of the Company and the investments wehave made in these brands to date underwrite the future potential. We wouldhighlight that the current licence with Yves Saint Laurent runs up to 31December 2006. With our strong record of successful brand acquisitions and development, we arewell placed to continue to develop this strategy adding further world wideprestigious brand and licensing opportunities. We expect to release our preliminary results for the year ended 31 March 2005 on8 June 2005 and we are confident in achieving market estimates. For further information contact: MarchpoleGreg Tufnell - Chief ExecutiveJustin Hampshire - Finance Director020 7908 7700 Shore CapitalAlex Borrelli020 7408 4090 Buchanan CommunicationsTim Thompson / Nicola Cronk020 7466 5000 Notes to editors:Marchpole announced in November 2004, strong interim results for the six monthsended 2 October 2004, with operating profit up 194% to £2.6 million (2003:£0.9m) on increased turnover of £15.7 million (2003 : £8.0 million). This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Feb 202012:00 pmRNSPositive feedback from phase 2 meeting with FDA
25th Feb 20203:00 pmRNSHolding(s) in Company
21st Feb 20202:31 pmRNSHolding(s) in Company
21st Feb 20202:30 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 20204:06 pmRNSDirector and other PDMR Dealings
19th Feb 20208:00 amRNSEquity Investment
18th Feb 202011:00 amRNSPrice Monitoring Extension
13th Feb 202010:45 amRNSHolding(s) in Company
12th Feb 20204:00 pmRNSHolding(s) in Company
12th Feb 20201:00 pmRNSUpdate on Distribution
11th Feb 20203:00 pmRNSHolding(s) in Company
10th Feb 20202:06 pmRNSSecond Price Monitoring Extn
10th Feb 20202:00 pmRNSPrice Monitoring Extension
10th Feb 202012:00 pmRNSNovartis Financing; Purchase Agreement with Aspire
28th Jan 20202:05 pmRNSSecond Price Monitoring Extn
28th Jan 20202:00 pmRNSPrice Monitoring Extension
14th Jan 202012:00 pmRNSAdditional positive data from phase 2b study
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 202012:00 pmRNSMereo and Oncologie Global Licensing Agreement
6th Jan 20204:45 pmRNSHolding(s) in Company
2nd Jan 202011:05 amRNSSecond Price Monitoring Extn
2nd Jan 202011:00 amRNSPrice Monitoring Extension
31st Dec 201911:00 amRNSPrice Monitoring Extension
27th Dec 201911:05 amRNSSecond Price Monitoring Extn
27th Dec 201911:00 amRNSPrice Monitoring Extension
18th Dec 20192:22 pmRNSNotification of Major Holdings in Company
16th Dec 20192:17 pmRNSNotification of Holdings in Company
3rd Dec 20194:54 pmRNSPDMR Shareholding
27th Nov 20194:12 pmRNSDirector Shareholding
25th Nov 20195:02 pmRNSDirector Shareholding
22nd Nov 20195:09 pmRNSDirector/PDMR Shareholding
20th Nov 20192:31 pmRNSPDMR Shareholding
11th Nov 201911:05 amRNSSecond Price Monitoring Extn
11th Nov 201911:00 amRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSMereo BioPharma Phase 2b ASTEROID Study
18th Oct 20197:00 amRNSHoldings in Company
17th Oct 20192:20 pmRNSHoldings in Company
14th Oct 201912:21 pmRNSNotification of Director Dealing
7th Oct 20191:00 pmRNSFDA Fast Track Designation for Navicixizumab
4th Oct 20192:57 pmRNSPDMR Notification
2nd Oct 20193:54 pmRNSPDMR Notification
26th Sep 201912:04 pmRNSPDMR Dealing
25th Sep 201910:38 amRNSPDMR Dealing
24th Sep 20191:00 pmRNSDirector Dealing
20th Sep 20192:22 pmRNSDirector Shareholding
17th Sep 20197:00 amRNSInterim results for 6 months ended June 30, 2019
13th Sep 20193:30 pmRNSDirectors' details update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.